1
|
Kaunitz AM, Nelson AL, Barnhart KT, Thomas MA, Archer DF, Chiodo JA, Previtera M, Korner P. IMPACT OF APPLICATION SITE AND BODY MASS INDEX ON ADHESION AND TOLERABILITY OF A LEVONORGESTREL/ETHINYL ESTRADIOL TRANSDERMAL CONTRACEPTIVE DELIVERY SYSTEM. Fertil Steril 2021. [DOI: 10.1016/j.fertnstert.2021.07.782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
2
|
Nelson AL, Kaunitz AM, Kroll R, Simon JA, Poindexter AN, Castaño PM, Ackerman RT, Flood L, Chiodo JA, Garner EI. Efficacy, safety, and tolerability of a levonorgestrel/ethinyl estradiol transdermal delivery system: Phase 3 clinical trial results. Contraception 2020; 103:137-143. [PMID: 33259782 DOI: 10.1016/j.contraception.2020.11.011] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
OBJECTIVE To assess the contraceptive efficacy, safety, and tolerability of a contraceptive transdermal delivery system, (TDS; TWIRLAⓇ) containing levonorgestrel (LNG) and ethinyl estradiol (EE). STUDY DESIGN This single-arm, open-label, multicenter, 1-year (13 cycle), phase 3 study enrolled sexually active women ≥18 years old at risk for pregnancy irrespective of body mass index (BMI). Women used patches in 28-day cycles (3 consecutive administrations of 7-day patches followed by 7 days off-treatment/patch-free week). We assessed contraceptive efficacy by the Pearl Index (PI) in women 18 to 35 years, excluding cycles without intercourse or when other contraceptive methods were used. RESULTS The study enrolled 2032 demographically diverse women in the US, of which 35.3% had a BMI ≥30 kg/m2. In the primary efficacy analysis, the PI (95% confidence interval) was 5.8 (4.5-7.2) pregnancies per 100 woman-years. PIs trended higher as BMI increased; the PI was 4.3 (2.9-5.8) in women with BMI <30 kg/m2 and 8.6 (5.8-11.5) in women with BMI ≥30 kg/m2. Hormone-related treatment-emergent adverse events included nausea (4.1%) and headache (3.6%); 11% of women discontinued due to adverse events. Four women (all with BMIs ≥30 kg/m2) reported thromboembolic events considered related to treatment. CONCLUSIONS The low-dose LNG/EE TDS was effective in preventing pregnancy in a population of women representative of US demographics. Efficacy was reduced in women with BMI ≥30 kg/m2. The TDS safety and tolerability profile was consistent with other similar dose combined hormonal contraceptives. Results of this phase 3 study supported the US Food and Drug Administration approval of TWIRLAⓇ for prevention of pregnancy in women with BMI <30 kg/m2. IMPLICATIONS TDS (120 µg/day levonorgestrel and 30 µg/day ethinyl estradiol) is an effective, low-dose transdermal contraceptive patch with favorable tolerability profile approved for prevention of pregnancy in women with BMI <30 kg/m2. TDS has reduced effectiveness in women with BMI ≥30 kg/m2.
Collapse
Affiliation(s)
| | - Andrew M Kaunitz
- University of Florida College of Medicine-Jacksonville, Jacksonville, FL, USA
| | - Robin Kroll
- University of Washington, Seattle Women's Health, Research, Gynecology, Seattle, WA, USA
| | - James A Simon
- George Washington University School of Medicine, Washington, DC, USA
| | | | - Paula M Castaño
- Columbia University Irving Medical Center, New York, NY, USA
| | | | - Lisa Flood
- ALK-Abello, Inc. Pharmaceuticals, Bedminster, NJ, USA
| | | | | | | |
Collapse
|
3
|
Kimble TD, Poindexter A, Barnhart K, Castaño PM, Chen BA, Chiodo JA, Garner EIO. Body mass index and weight are predictors of pregnancy in a phase 3 multicenter contraceptive efficacy study of AG200-15, a low-dose combination hormonal contraceptive patch. Contraception 2018. [DOI: 10.1016/j.contraception.2018.07.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
4
|
Edelman A, Trussell J, Aiken ARA, Portman DJ, Chiodo JA, Garner EIO. The emerging role of obesity in short-acting hormonal contraceptive effectiveness. Contraception 2017; 97:371-377. [PMID: 29269251 DOI: 10.1016/j.contraception.2017.12.012] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2017] [Revised: 12/08/2017] [Accepted: 12/08/2017] [Indexed: 10/18/2022]
Affiliation(s)
- Alison Edelman
- Oregon Health & Science University, Department of Ob-Gyn UHN 50, 3181 Sam Jackson Park Rd, Portland, OR 97239.
| | - James Trussell
- Princeton University, Office of Population Research, Wallace Hall, Princeton, NJ 08544.
| | - Abigail R A Aiken
- University of Texas at Austin, LBJ School of Public Affairs, P.O. Box Y, Austin, TX, 78713.
| | - David J Portman
- Sermonix Pharmaceuticals, 3000 East Main St, Suite 218, Columbus, OH, 43209.
| | | | | |
Collapse
|
5
|
Nelson AL, Kaunitz AM, Kroll R, Simon JA, Poindexter AN, Chiodo JA, Flood L, Garner EIO. Bleeding and spotting results from the secure trial: a phase 3 study of the AG200-15 investigational transdermal contraceptive patch. Contraception 2017. [DOI: 10.1016/j.contraception.2017.07.070] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
6
|
Dunlap ME, Hauptman PJ, Amin AN, Chase SL, Chiodo JA, Chiong JR, Dasta JF. Current Management of Hyponatremia in Acute Heart Failure: A Report From the Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia (HN Registry). J Am Heart Assoc 2017; 6:JAHA.116.005261. [PMID: 28775063 PMCID: PMC5586406 DOI: 10.1161/jaha.116.005261] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Background Hyponatremia (HN) occurs commonly in patients with acute heart failure and confers a worse prognosis. Current HN treatment varies widely, with no consensus. This study recorded treatment practices currently used for patients hospitalized with acute heart failure and HN. Methods and Results Data were collected prospectively from 146 US sites on patients hospitalized with acute heart failure and HN (serum sodium concentration [Na+] ≤130 mEq/L) present at admission or developing in the hospital. Baseline variables, HN treatment, and laboratory values were recorded. Of 762 patients, median [Na+] was 126 mEq/L (interquartile range, 7) at baseline and increased to 130 mEq/L at discharge. Fluid restriction was the most commonly prescribed therapy (44%), followed by no specific HN treatment beyond therapy for congestion (23%), isotonic saline (5%), tolvaptan (4%), and hypertonic saline (2%). Median rate of change in [Na+] varied by treatment (0.5 [interquartile range, 1.0] to 2.3 [8.0] mEq/L/d) and median treatment duration ranged from 1 (interquartile range, 1) to 6 (5) days. Fluid restriction and no specific HN treatment resulted in similar changes in [Na+], and were least effective in correcting HN. Few patients (19%) had [Na+] ≥135 mEq/L at discharge. Conclusions The most commonly used treatment approaches for HN (fluid restriction and no specific treatment) in acute heart failure increased [Na+] minimally, and most patients remained hyponatremic at discharge.
Collapse
Affiliation(s)
- Mark E Dunlap
- MetroHealth Campus of Case Western Reserve University, Cleveland, OH
| | | | | | - Sandra L Chase
- Otsuka Product Development & Commercialization, Inc.,, Princeton, NJ
| | - Joseph A Chiodo
- Otsuka Product Development & Commercialization, Inc.,, Princeton, NJ
| | - Jun R Chiong
- Loma Linda University Medical Center, Loma Linda, CA
| | - Joseph F Dasta
- The University of Texas at Austin College of Pharmacy, Hutto, TX
| |
Collapse
|
7
|
Verbalis JG, Greenberg A, Burst V, Haymann JP, Johannsson G, Peri A, Poch E, Chiodo JA, Dave J. Diagnosing and Treating the Syndrome of Inappropriate Antidiuretic Hormone Secretion. Am J Med 2016; 129:537.e9-537.e23. [PMID: 26584969 DOI: 10.1016/j.amjmed.2015.11.005] [Citation(s) in RCA: 65] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/26/2015] [Revised: 10/29/2015] [Accepted: 11/03/2015] [Indexed: 11/19/2022]
Abstract
BACKGROUND The syndrome of inappropriate antidiuretic hormone secretion is the most common cause of hyponatremia in clinical practice, but current management of hyponatremia and outcomes in patients with syndrome of inappropriate antidiuretic hormone secretion are not well understood. The objective of the Hyponatremia Registry was to assess the current state of management of hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion in diverse hospital settings, specifically which diagnostic and treatment modalities are currently used and how rapidly and reliably they result in an increase in serum sodium concentration ([Na(+)]). A secondary objective was to determine whether treatment choices and outcomes differ across the United States and the European Union. METHODS The Hyponatremia Registry recorded selected diagnostic measures and use, efficacy, and outcomes of therapy for euvolemic hyponatremia diagnosed clinically as syndrome of inappropriate antidiuretic hormone secretion in 1524 adult patients with [Na(+)] ≤130 mEq/L (1034 from 146 US sites and 490 from 79 EU sites). A subgroup of patients with more rigorously defined syndrome of inappropriate antidiuretic hormone secretion via measurement of relevant laboratory parameters was also analyzed. RESULTS The most common monotherapy treatments for hyponatremia in syndrome of inappropriate antidiuretic hormone secretion were fluid restriction (48%), isotonic (27%) or hypertonic (6%) saline, and tolvaptan (13%); 11% received no active agent. The mean rate of [Na(+)] change (mEq/L/d) was greater for all active therapies than no active treatment. Hypertonic saline and tolvaptan produced the greatest mean rate of [Na(+)] change (interquartile range, both 3.0 [6.0] mEq/L/d) compared with lower interquartile range rates of [Na(+)] change for isotonic saline (1.5 [3.0] mEq/L/d) and fluid restriction (1.0 [2.3] mEq/L/d). The general pattern of responses was similar in both the US and EU cohorts. At discharge, [Na(+)] was <135 mEq/L in 75% of patients and ≤130 mEq/L in 43% of patients. Overly rapid correction occurred in 10.2% of patients. CONCLUSIONS Current treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion often uses therapies with limited efficacy; the most commonly chosen monotherapy treatments, fluid restriction and isotonic saline, failed to increase the serum [Na(+)] by ≥5 mEq/L in 55% and 64% of monotherapy treatment episodes, respectively. Appropriate laboratory tests to diagnose syndrome of inappropriate antidiuretic hormone secretion were obtained in <50% of patients; success rates in correcting hyponatremia were significantly higher when such tests were obtained. Few outcome differences were found between the United States and the European Union. A notable exception was hospital length of stay; use of tolvaptan was associated with significantly shorter length of stay in the European Union but not in the United States. Despite the availability of effective therapies, most patients with syndrome of inappropriate antidiuretic hormone secretion were discharged from the hospital still hyponatremic.
Collapse
Affiliation(s)
- Joseph G Verbalis
- Division of Endocrinology and Metabolism, Georgetown University Medical Center, Washington, DC.
| | | | - Volker Burst
- Department 2 of Internal Medicine and Center for Molecular Medicine, University Hospital of Cologne, Cologne, Germany
| | | | - Gudmundur Johannsson
- Department of Endocrinology, Institute of Medicine, University of Göteborg and Sahlgrenska University Hospital, Göteborg, Sweden
| | | | - Esteban Poch
- Nephrology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
| | | | - Jiten Dave
- Otsuka Pharmaceuticals Europe Ltd, Wexham, United Kingdom
| |
Collapse
|
8
|
Castillo JJ, Glezerman IG, Boklage SH, Lamerato LE, Chiodo JA, Tidwell BA, Schulman KL. Abstract P5-08-49: Incidence and prognostic importance of hyponatremia in a cohort of patients with breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p5-08-49] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: It has been suggested that hyponatremia (HN) may be a negative prognostic factor in patients with cancer but little research has been conducted specifically in breast cancer (BC). We measured the incidence of hyponatremia (hypervolemic and euvolemic) after BC diagnosis and its prognostic importance for progression free (PFS) and overall survival (OS).
Methods: This retrospective cohort analysis utilized data from the Henry Ford Health System electronic medical record, tumor registry, and administrative databases. Study data were collected electronically and via medical record abstraction. Adults diagnosed (2002-2010) with incident invasive BC were selected if they had a known disease stage at the time of tumor registration, were classified as an analytic case, had ≥ 1 administration of chemo/radiation therapy ≤ 6 months from diagnosis, met continuous enrollment thresholds, and did not experience hypovolemic HN post index. Only the first tumor registered from each patient was considered study-eligible. Hypervolemic or euvolemic HN incidence (serum sodium ≤ 135 mEq/L) was measured per 1000 person-years (PY) of observation and classified as mild (131–135 mEq/L), moderate (125–130 mEq/L) or severe (<125 mEq/L) based on the lowest observed value. A Cox proportional hazards model was used to assess the prognostic value of HN as a time-varying covariate on PFS and OS while controlling for age, race, income, morphology code, diagnosis year, cancer stage at diagnosis, performance status at diagnosis, and hormone receptor status.
Results: 527 patients were eligible (mean [SD] age 56.4±11.3 years, 61% Caucasian). Mean (SD) follow-up was 3.7±2.8 years. Eighty-five percent of patients had infiltrating ductal carcinoma; 72% and 65% had estrogen or progesterone sensitive tumor, respectively; 35% were HER2 positive; and 15% had triple negative disease. Eighty-two percent of patients had early stage (I, II) disease at time of diagnosis. HN episodes (n=377) occurred in 204 patients (39%) at a rate of 193 per 1000 PY (95% CI, 174–213.5), with 89% of the total episodes (337/377) classified as mild, 10% (36/377) as moderate, and 1% (4/377) as severe. Additionally, 7% of all BC patients (37/527) had at least one episode of moderate/severe HN. Median time to first HN episode was 174.5 days and the median HN episode duration was 24.0 days. Five year OS in patients developing HN was 92%, compared to 97% in patients who never developed HN. Hazard ratio (95% CI, p-value) for OS in the HN group was 4.4 (1.5-12.7; p=0.006) after controlling for age, diagnosis year, race, income, morphology, cancer stage, performance status, and hormone receptor status. Fifty patients had progressive disease during follow-up with a mean (SD) time to progression of 763.4 (758.1) days. Hazard ratio (95% CI, p-value) for PFS in the HN group was 1.4 (0.8-2.7; p=0.262) after controlling for age, race, income, morphology, cancer stage, performance status, and hormone receptor status.
Conclusions: Incidence of hypervolemic or euvolemic HN is high (39%) after a BC diagnosis, and the occurrence is associated with significantly poorer OS. A significant impact on disease progression was not observed.
Citation Format: Castillo JJ, Glezerman IG, Boklage SH, Lamerato LE, Chiodo JA, Tidwell BA, Schulman KL. Incidence and prognostic importance of hyponatremia in a cohort of patients with breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-08-49.
Collapse
Affiliation(s)
- JJ Castillo
- Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, NY, NY; Otsuka America Pharmaceutical, Inc., Princeton, NJ; Henry Ford Health System, Detroit, MI; Outcomes Research Solutions, Inc., Waltham, MA
| | - IG Glezerman
- Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, NY, NY; Otsuka America Pharmaceutical, Inc., Princeton, NJ; Henry Ford Health System, Detroit, MI; Outcomes Research Solutions, Inc., Waltham, MA
| | - SH Boklage
- Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, NY, NY; Otsuka America Pharmaceutical, Inc., Princeton, NJ; Henry Ford Health System, Detroit, MI; Outcomes Research Solutions, Inc., Waltham, MA
| | - LE Lamerato
- Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, NY, NY; Otsuka America Pharmaceutical, Inc., Princeton, NJ; Henry Ford Health System, Detroit, MI; Outcomes Research Solutions, Inc., Waltham, MA
| | - JA Chiodo
- Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, NY, NY; Otsuka America Pharmaceutical, Inc., Princeton, NJ; Henry Ford Health System, Detroit, MI; Outcomes Research Solutions, Inc., Waltham, MA
| | - BA Tidwell
- Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, NY, NY; Otsuka America Pharmaceutical, Inc., Princeton, NJ; Henry Ford Health System, Detroit, MI; Outcomes Research Solutions, Inc., Waltham, MA
| | - KL Schulman
- Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, NY, NY; Otsuka America Pharmaceutical, Inc., Princeton, NJ; Henry Ford Health System, Detroit, MI; Outcomes Research Solutions, Inc., Waltham, MA
| |
Collapse
|
9
|
Castillo JJ, Glezerman IG, Boklage SH, Chiodo JA, Tidwell BA, Lamerato LE, Schulman KL. Prognostic significance of hypervolemic or euvolemic hyponatremia in patients with lymphoma, breast, lung, or colorectal cancer. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e17554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Ilya G. Glezerman
- Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY
| | | | | | | | | | | |
Collapse
|
10
|
Chiong JR, Hauptman PJ, Dunlap ME, Chiodo JA, Chase SL. Hospital Management of Hyponatremia in Patients with Heart Failure: Final Report from the HN Registry. J Card Fail 2014. [DOI: 10.1016/j.cardfail.2014.06.177] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|